Xencor has begun the Phase 1 clinical trial of humanised monoclonal antibody XmAb5871 for the treatment of autoimmune diseases.
XmAb5871 uses a selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (FcyRIIb), and is designed to help in the suppression of autoimmune response.
Preclinical studies demonstrated that XmAb5871 suppresses autoimmune response in humanised mouse models of systemic lupus erythematosus, without the depletion of B cells.
The study results suggest that XmAb5871 could be an effective immunosuppressant in multiple indications, including lupus and rheumatoid arthritis.
The endpoints of the Phase I study include safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData